Print page content Print
Increase text size Decrease text size
Text Size



How are vaccines tested and evaluated?

The FLUVAC INNOVATOR line of vaccines helps keep your horse healthy and provides him with broad protection against newly emerging and conventional equine influenza virus (EIV) strains as well as equine herpesvirus (EHV-1 and EHV-4).2-7

A total of six studies have demonstrated FLUVAC INNOVATOR is effective against emerging equine influenza strains.2-7 Zoetis regularly tests FLUVAC INNOVATOR to ensure our vaccine continues to be effective against emerging EIV isolates.

       Video: How are vaccines tested and evaluated?

Equine influenza is one of the most common respiratory diseases in horses, spreading by aerosol transmission (coughing) from horse-to-horse in distances as far as 50 yards. That’s why having an effective, trusted vaccine is so important.

When you choose the most trusted vaccine to help protect your horses, you can rest easy because FLUVAC INNOVATOR is backed by the most comprehensive Equine Immunization Support Guarantee in the industry.

Make Following the USEF Vaccination Requirements Easy with FLUVAC INNOVATOR

As of December 1, 2015, all horses entering the grounds of a USEF-licensed competition must be accompanied by documentation of equine influenza virus (EIV) and equine herpesvirus (EHV) vaccinations within the previous 6 months. Horses without documentation may be required to leave the competition grounds.

Get clarity on the new USEF Vaccination Requirements – watch Dr. Kent Allen, chairman of the USEF Drug and Medications and Veterinary Committee explain the rule.

USEF Vaccination Rule Update

FLUVAC INNOVATOR makes preparing your records even easier. Your veterinarian can simply apply the product label sticker that is provided with each dose on the USEF record to quickly record your horse’s vaccination.

Zoetis Equine Vaccine Antigen Chart

Collapse All
    • Vaccination before exposure is the best way to combat EIV.8
    • At-risk horses (those less than 6 years of age, senior horses and horses that may be frequently exposed to EIV at outside events) should be vaccinated for EIV every six months.9
    • FLUVAC INNOVATOR is the only vaccine with EIV strain KY/97 that has demonstrated protection against heterologous challenge with EIV strain OH/03.3
    • In a study, FLUVAC INNOVATOR has been shown to be cross-reactive against three newly emerging equine influenza viruses, including Ayrshire 2013 (AY/13) a European Clade 2 isolate, Kentucky 2014 (KY/14), and Texas 2012 (TX/12) recent North American Clade 1 isolates.7
    • FLUVAC INNOVATOR is the only EIV vaccine shown to help protect against clinical signs for seven months against a heterologous, dual-strain challenge.2
    • In addition to helping protect against EIV, FLUVAC INNOVATOR vaccines also contain both EHV-1 and EHV-4 to help protect against rhinopneumonitis.
    • Only INNOVATOR vaccines are adjuvanted with MetaStim® to help amplify the horse’s immune response.10,11
    • Inject 1-mL dose intramuscularly using aseptic technique. Administer a second 1-mL dose 3 to 4 weeks after the first dose.
    • A 1-mL booster dose should be given annually.
    • Always read and follow label indications.
    • Early revaccination may be advisable when horses are faced with an outbreak or with other conditions that might make exposure likely.

    Store in the dark at 2° to 7° C (35° to 45° F). AVOID FREEZING. SHAKE WELL. Use entire contents when first opened. In some instances, transient local reactions may occur at the injection site. Do not vaccinate within 21 days before slaughter. In case of anaphylactoid reaction, administer epinephrine. Thimerosal, neomycin and polymyxin B are added as preservatives. For veterinary use only.

  • 1 Data on file, MDI sales data for FLUVAC INNOVATOR® as of 12/31/15, Zoetis LLC.

    2 Data on file, Study Report No. 671-02-001R, Zoetis LLC.

    3 Data on file, Study Report No. 671-08-004.R, Zoetis LLC.

    4 Data on file, Study Report No. 766-09-002.R, Zoetis LLC.

    5 Data on file, Study Report No. 10OREQBIO-01, Zoetis LLC.

    6 Data on file, Study Report No. 14OREQBIO-1, Zoetis LLC.

    7 Data on file, Study Report No. 15EQRGBIO-02, Zoetis LLC.

    8 The American Association of Equine Practitioners. Risk-Based Vaccination Guidelines. Equine Influenza. Available at: Accessed on August 5, 2016.

    9 The American Association of Equine Practitioners. Suspected Case of Contagious Infectious Respiratory Disease. Available at: Accessed August 5, 2016.

    10 Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of Antigen Specific Lymphocyte Responses in Healthy Horses Vaccinated with an Inactivated West Nile Virus Vaccine. Vet Immunol Immunop 2008;126(3-4):293–301.

    11 Davis EG, Bello NM, Bryan AJ, Hankins K, Wilkerson M. Characterisation of immune responses in healthy foals when a multivalent vaccine protocol was initiated at age 90 or 180 days. Equine Vet J. 2014. doi:10.1111/evj.12350.




Mon–Fri, 8:30am–6:30pm ET

This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.